![]() ![]() Ruf P, Bauer HW, Schoberth A, Kellermann C, Lindhofer H (2021). The leading molecule, catumaxomab is being evaluated in clinical trials for both advanced gastric cancer and non-muscle invasive bladder cancer. The current pipeline includes several treatments in development for blood cancer and solid tumors. LintonPharm has developed multiple bispecific antibody platforms with a great potential of refined safety and efficacy profiles, long-lasting vaccinal effects and CMC efficiency. is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases. Recently, catumaxomab was authorized by regulatory authorities in China, Taiwan (China) and South Korea to conduct a global Phase 3 clinical trial for treating patients with advanced gastric cancer (: NCT04222114). Catumaxomab destroys tumor cells by engaging T cell and accessory cell mediated cytotoxicity and has the potential to induce long-term vaccinal effects which has been verified in animal models. This bispecific antibody binds to a transmembrane glycoprotein on the tumor cell-the epithelial cell adhesion molecule (EpCAM)-and CD3 on the T cell, and also recruits immune accessory cells through FcγR binding. Ĭatumaxomab was approved by the European Medicines Agency in 2009 for the treatment of malignant ascites. Currently, the mainstay treatments of NMIBC include transurethral resection, chemotherapy and intravesical BCG. Based on the data and the developmental potential, catumaxomab could provide a feasible, safe, and efficacious therapy for NMIBC patients, if approved.īladder cancer is the 10th most commonly diagnosed cancer worldwide, with approximately 573,000 new cases in 2020 and roughly 75 percent are diagnosed as NMIBC. It is noted that catumaxomab was well tolerated and presented promising performance in tumor control. Based on encouraging pre-clinical data and clinical experience with patients who’ve received catumaxomab in the past through the compassionate use program, we are hopeful that catumaxomab will be a very promising immunotherapy candidate for patients with NMIBC BCG failure.”Ī recent publication indicated clinical benefits of catumaxomab as compassionate use in patients with EpCAM-positive recurrent NMIBC. “Patients with NMIBC BCG failure need new therapies due to the limitations of current treatments which bring poor prognosis, such as high rates of tumor recurrence, bladder dysfunction and lifelong intervention. “The initiation of our Phase 1 trial of catumaxomab for the treatment of NMIBC is an important step in our clinical program evaluating catumaxomab as targeted therapy in a broad range of cancers”, said Robert Li, PH.D., DABT, Co-founder and CEO of LintonPharm. GUANGZHOU, China I DecemI LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today announced that the first patient has been dosed in the Company’s Phase 1/2 clinical trial program for catumaxomab (: NCT04799847), a monoclonal bispecific antibody being studied for the treatment of Non-Muscle-Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG). try to disable them with the Adobe Extension Manager, depending on your installation, you have to maybe run the Manager wih root, terminal: sudo (drag here the. > Sometimes Old Plugins could also crash PS. > Another issue could be messed up fonts, use FontBook to scan your fonts, remove all which are marked RED But i forgot to maybe consider to reimplement the security thing mentioned in linked article. and i ran into another version of it, from one day to the other, PS crashed when i tried to use for e.g. > Font Setting in PS, set preview to small, if this isn´t set, PS will crash on using font tool, by rendering the font preview box > update to 12.0.4 or even 12.0.5 here you find a way to run "old" incompatible updater. You have to consider serveral things that could be an issue I went through a crazy voyage with my CS5 Creative Suite PS Version,
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |